SiRNA-loaded tetrahedral framework nucleic acid, preparation method thereof and application of siRNA-loaded tetrahedral framework nucleic acid in preparation of anti-aging drugs

Through the tetrahedral framework nucleic acid complex equipped with siRNA, the targeting and stability of siRNA during delivery is solved, and effective inhibition of rapamycin complex 1 is achieved, which extends cell life and slows down the aging process. , significantly improve the therapeutic effect of anti-aging drugs.

CN118931903AActive Publication Date: 2024-11-12SICHUAN UNIV
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411051814.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-01
Publication Date
2024-11-12
Estimated Expiration
2044-08-01

AI Technical Summary

Technical Problem

Existing siRNAs are difficult to target into cells during delivery, and are easily degraded by nucleases and cleared by kidneys, resulting in poor treatment results.

Method used

Using tetrahedral framework nucleic acid complex equipped with siRNA, tetrahedral framework nucleic acid formed by self-assembling siRNA with four single strands of DNA and two single strands of RNA in a specific sequence, combined with pharmaceutical excipients to prepare anti-aging drugs, using heating and cooling reactions Conditionally stable complex.

Benefits of technology

It improves the targeting and stability of siRNA, enhances the inhibitory effect on the expression of rapamycin complex 1, extends the cell life span, slows down the aging process, and significantly improves the therapeutic effect of anti-aging drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118931903A_ABST
    Figure CN118931903A_ABST
Patent Text Reader

Abstract

The invention provides a tetrahedral framework nucleic acid carrying siRNA, a preparation method of the tetrahedral framework nucleic acid and application of the tetrahedral framework nucleic acid in preparation of anti-aging drugs, and belongs to the technical field of medicines. The siRNA for inhibiting the expression of the rapamycin compound 1 (mTORC1) is loaded on the tetrahedral framework nucleic acid, the formed tetrahedral framework nucleic acid compound can play a synergistic anti-aging role, and the tetrahedral framework nucleic acid compound has a good application prospect in preparation of anti-aging drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of medical technology, and specifically relates to a tetrahedral framework nucleic acid carrying siRNA, a preparation method thereof, and use thereof in the preparation of anti-aging drugs. Background Art

[0002] In recent years, aging has gradually become a major development trend of the global population. As people age, their physiological functions gradually decline. Therefore, the concept of healthy aging has received increasing attention. Maintaining the physical functions of the elderly and improving their quality of life is one of the important research directions in the field of anti-aging.

[0003] The rapamycin complex 1 (mTORC1) is the center of the cell's response to external stimuli to regulate growth and metabolism. With age, the signaling level of mTORC1 increases abnormally, leading to aging-related diseases. Inhibition of mTORC1 has been shown to extend the lifespan of a variety of preclinical species (including yeast, nematodes, fruit flies, mice, etc.). Raptor (mTORC1-specific component) gene knockout or mutation can extend the lifespan of nematodes. Tissue-specific Raptor deletion can alleviate a variety of aging-related pathologies by inhibiting mTORC1 signaling. Therefore, targeting mTORC1 provides an innovative strategy for anti-aging.

[0004] With the continuous development of nano-delivery systems, more and more therapeutic siRNA drugs have entered the clinical trial stage, and some have even been approved for marketing. However, single siRNA has problems such as difficulty in targeting cells, degradation of siRNA by nucleases during delivery, and renal clearance, and the therapeutic effect needs to be further improved. Summary of the invention

[0005] In order to solve the defects of the prior art, the purpose of the present invention is to provide a tetrahedral framework nucleic acid carrying siRNA and a preparation method thereof and use thereof in the preparation of anti-aging drugs.

[0006] The invention provides a tetrahedral framework nucleic acid complex, which is a product prepared using siRNA and tetrahedral framework nucleic acid as raw materials, wherein the molar ratio of siRNA to tetrahedral framework nucleic acid is 1:(0.5-10), and siRNA is siRNA that inhibits the expression of rapamycin complex 1.

[0007] Furthermore, the molar ratio of the siRNA to the tetrahedral framework nucleic acid is 1:1.

[0008] Furthermore, the tetrahedral framework nucleic acid is self-assembled from four DNA single strands, and the sequences of the four DNA single strands are shown as SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3 and SEQ ID NO.4 respectively;

[0009] The siRNA is self-assembled from two RNA single strands, and the sequences of the two RNA single strands are shown as SEQ ID NO.5 and SEQ ID NO.6 respectively.

[0010] The present invention also provides a method for preparing the tetrahedral framework nucleic acid complex, which comprises the following steps: mixing siRNA and tetrahedral framework nucleic acid and reacting them to obtain the tetrahedral framework nucleic acid complex.

[0011] Furthermore, the reaction conditions are to first heat the reaction and then cool the reaction;

[0012] The heating reaction temperature is 80-100°C and the time is 5-15min;

[0013] The temperature of the cooling reaction is 0-10°C and the time is 10-30 minutes.

[0014] Furthermore, the heating reaction temperature is 95°C and the time is 10 minutes;

[0015] The temperature of the cooling reaction is 4°C and the time is 20 minutes.

[0016] The present invention also provides the use of the tetrahedral framework nucleic acid complex in preparing anti-aging drugs.

[0017] Furthermore, the drug is a drug that inhibits the expression of Raptor mRNA and / or inhibits the expression of aging markers.

[0018] Furthermore, the drug is a drug that reduces the number of senescent cells.

[0019] Furthermore, the drug is a pharmaceutical preparation prepared with the tetrahedral framework nucleic acid complex as an active ingredient and pharmaceutically acceptable excipients.

[0020] The experimental results show that the present invention carries siRNA that inhibits the expression of rapamycin complex 1 onto the tetrahedral framework nucleic acid, and the formed tetrahedral framework nucleic acid complex can exert a synergistic anti-aging effect. The tetrahedral framework nucleic acid complex has good application prospects in the preparation of anti-aging drugs.

[0021] Obviously, according to the above contents of the present invention, in accordance with common technical knowledge and customary means in the art, without departing from the above basic technical ideas of the present invention, other various forms of modification, replacement or change may be made.

[0022] The above contents of the present invention are further described in detail below through specific implementation methods in the form of examples. However, this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples. All technologies realized based on the above contents of the present invention belong to the scope of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 .siR-TDN box Structural characterization results: (a) complex siR-TDN box Schematic diagram of the structure of siR-TDN; (b) box HPLC chromatogram; (c) 5% PAGE image showing that cy5 fluorescent siRNA was successfully loaded into siR-TDN box In the complex; (d) siR-TDN box Dynamic light scattering measurement of particle size; (e) siR-TDN box Zeta potential of siR-TDN; (f) box Transmission electron microscopy image (scale bar: 100 nm); (g) siR-TDN box AFM images (scale bar: 50 nm); (h) 5% PAGE gel image showing that siR-TDN was incubated with different concentrations (0%, 1%, 2%, 4%, 6%, 8% and 10%) of fetal bovine serum at 37°C for 24 h box (Merged), TDN box (blue) and siRNA (red); (i) 5% PAGE gel image showing that siR-TDN box Serum stability in 10% fetal bovine serum for 0, 1, 2, 4, 6, 12 and 24 h; (j) 5% PAGE gel image shows that at 37°C, siR-TDN box and unloaded free siRNA after 1 h of incubation; (k) 5% PAGE gel image shows that siRNA and siR-TDN after incubation with 25 μg / mL RNase A at 37°C for different time periods (0, 1, 2, 4, 6, 12, 24 h). box The free amount.

[0024] Figure 2 .siR-TDN boxDistribution experimental results in cells and tissues: (a) siR-TDN box Schematic diagram of sample injection; (b) Flow cytometry analysis of cells exposed to siR-TDN box Cellular uptake of young and aged fibroblasts after different time periods (3, 6 and 12 h); (c) Confocal fluorescence images showing siR-TDN in young and aged fibroblasts after 3, 6 and 12 h of incubation box Cellular uptake (blue: DAPI, green: Cytoskeleton, red: siR-TDN box ; Scale bar: 20 μm); (d) Statistical analysis of cell uptake rate by flow cytometry; (e) Statistical analysis of fluorescence intensity of confocal images; (f) Intraperitoneal injection of siR-TDN box In vivo fluorescence images of C57BL / 6 mouse organs at different times (0.5, 1, 3, 6, 12, and 24 h) after operation.

[0025] Figure 3 . Anti-cell aging experimental results: (a) Schematic diagram of anti-aging cell experimental treatment; (b) Detection of Raptor mRNA expression by qPCR (senescent cells and siRNA, TDN box 、siR-TDN box incubated for 24 h); (c) representative images of senescent cells and control cells in the presence of SA-β-Gal dye (green, scale bar: 100 μm); (d) statistical analysis of the percentage of SA-β-Gal-positive cells in mouse NIH / 3T3 cells after treatment; (e) immunoblotting to detect changes in the protein levels of senescence markers (p21 and p16), mTORC1 pathway (Raptor, S6 and p-S6), and SASP factors (IL-6 and TNF-α) after doxorubicin-induced senescence; (f) determination of the expression levels of senescent NIH / 3T3 proteins p21, p16, Raptor, p-S6 / S6, IL-6, and TNF-α; visualization of the percentage of p21-positive (g), p16-positive (h), IL-6-positive (i), and TNF-α-positive (j) cells after senescence induction (cytoskeleton: green; nucleus (DAPI): blue; target protein: red, scale bar: 20 μm).

[0026] Figure 4 . Experimental results of anti-aging of doxorubicin-exposed mice: (a) Schematic diagram of mouse experiment; (b) Survival curve of accelerated aging mice; (Dox n=20, Dox+siR-TDN boxn = 20); (c) quantification of changes in grip strength test; turning time (d) and climbing down time (e) in the climbing pole test; (f) time spent on the rotarod; (g) total distance landed on the rotarod; (h) representative images (left) and quantification (right) of H&E staining of liver sections, (scale bar, 50 μm); (i) visualization (left) and quantification (right) of the percentage of SA-β-gal-positive senescent cells in the liver, (scale bar, 100 μm); (j) left: representative visualization of p21 immunofluorescence in the liver of doxorubicin-exposed mice after the indicated treatments (scale bar, 50 μm), right: quantification of the percentage of p21-positive senescent cells in the liver.

[0027] Figure 5 . Results of the physical function experiment on anti-aging mice: (a) siR-TDN box Experimental design for treating aged mice; (b) Appearance of mice (representative images of young mice, aged mice, and treated aged mice); (c) Grip strength of mice in each group; (d) Turning time of mice in climbing pole test; (e) Time for mice to climb down in climbing pole test; (f) Time mice stayed on the rotating rod in rotating rod test; (g) Total distance mice moved on the rotating rod in rotating rod test; (h) Open field test; (i) Time and distance mice passed through the central area in the open field test, and the total time and distance mice moved in the new environment; (j) Serum biochemical test (normal saline or siR-TDN box Changes in serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), and urea (UREA) levels in young and old mice after 2 months of treatment); (k) blood glucose during intraperitoneal glucose tolerance test.

[0028] Figure 6 . Experimental results of age-related changes in mice resistant to natural aging: (a) Visualization of senescence-associated galactosidase staining (SA-β-gal) in the liver, kidney, and lung of 3-month-old and 19-month-old mice (scale bar, 50 μm); (b) Representative H&E images of the effects on aged mice; (c) Representative immunofluorescence images of p21+ cells in the liver, kidney, and lung of aged mice (scale bar, 50 μm); (d, e) Immunoblotting to detect protein expression of senescence markers (p21 and p16) and mTORC1 pathway (Raptor, S6, and p-S6) in the liver, kidney, and lung of aged mice (scale bar, 50 μm). DETAILED DESCRIPTION

[0029] The raw materials and equipment used in the present invention are all known products, which are obtained by purchasing commercially available products.

[0030] Example 1: Preparation of tetrahedral framework nucleic acid carrying siRNA

[0031] A double-stranded siRNA (including carrier strand and cargo strand, side length 21 bp, see Table 1) and four single-stranded DNA strands (S1-S4, side length 30 bp, see Table 1) were added to TM buffer (1×10 -4 M Tris-HCl, 5 × 10 -4 M MgCl2·6H2O, pH=8.0) and the final concentration of the five chains was 1 μM. The entire reaction system was heated to 95°C in a thermal cycler, and then quickly cooled to 4°C and maintained for 20 minutes to obtain a tetrahedral framework nucleic acid (siR-TDN) carrying siRNA. box ) and stored at 4°C until use.

[0032] Table 1. Specific sequences of double-stranded siRNA and four single-stranded DNA

[0033]

[0034] *Lowercase letters represent RNA base sequences, and uppercase letters represent DNA base sequences.

[0035] The following is a control sample preparation.

[0036] Comparative Example 1: Preparation of Tetrahedral Framework Nucleic Acids

[0037] Four single-stranded DNAs (S1-S4, 30 bp in length, see Table 1) were added to TM buffer (1×10 -4 M Tris-HCl, 5 × 10 -4 M MgCl2·6H2O, pH=8.0) and the final concentration of the four chains was 1 μM. The entire reaction system was heated to 95°C in a thermal cycler, and then quickly cooled to 4°C and maintained for 20 minutes to obtain tetrahedral framework nucleic acids (tFNAs, abbreviated as TDN box ), and stored at 4°C for later use. Control Example 2, Preparation of NC-siRNA

[0038] A double-stranded siRNA (including carrier strand and cargo strand) was added to TM buffer (1×10 -4 M Tris-HCl, 5 × 10 -4 M MgCl2·6H2O, pH=8.0), and the final concentration of double-stranded siRNA was 1 μM. The entire reaction system was heated to 95°C in a thermal cycler, and then rapidly cooled to 4°C and maintained for 20 minutes to obtain NC-siRNA, which was stored at 4°C for later use.

[0039] Among them, the sequence of NC-siRNA is:

[0040] sense:UUCUCCGAACGUGUCACGUTT(SEQ ID NO.7);

[0041] anti-sense: ACGUGACACGUUCGGAGAATT (SEQ ID NO. 8).

[0042] The beneficial effects of the present invention are demonstrated by experimental examples below.

[0043] Experimental Example 1: Structural Characterization of Products

[0044] 1. Experimental methods

[0045] Verification of siR-TDN by polyacrylamide gel electrophoresis (PAGE), high-performance capillary electrophoresis (HPCE), transmission electron microscopy (TEM), and atomic force microscopy (AFM) box Whether the synthesis is successful and the size and shape of tFNAs. Dynamic light scattering (DLS) was used to measure the siR-TDN box Particle size and zeta potential.

[0046] 2. Experimental results

[0047] Figure 1 (ag) shows siR-TDN box The structural characterization results. Figure 1 b siR-TDN was verified by high performance liquid chromatography (HPCE) box Synthesis and molecular weight, Figure 1 c shows that siRNA was successfully loaded into siR-TDN box In the complex, Figure 1 (dg) The results showed that siR-TDN box The molecular weight (about 413 bp) is slightly larger than that of tFNAs (about 337 bp). box The average size is about 15.75nm and the Zeta potential is about -6.66mV. Transmission electron microscopy (TEM) and atomic force microscopy (AFM) images show that siR-TDN box Exhibiting a unique tetrahedral morphology.

[0048] Experimental Example 2: Stability Experiment

[0049] 1. Experimental methods

[0050] Storage stability, serum stability and enzyme stability were tested by polyacrylamide gel electrophoresis (PAGE), and the specific operation was as follows:

[0051] (1) Storage stability: The samples prepared in Example 1 were placed in an environment of 4° C. and 25° C. for 1 to 7 days to test the storage stability;

[0052] (2) Serum stability: The samples prepared in Example 1 were incubated with fetal bovine serum of different concentrations (0%, 1%, 2%, 4%, 6%, 8% and 10%) at 37° C. for 24 h, or with 10% fetal bovine serum for different reaction times (0, 1, 2, 4, 6, 12 and 24 h) to test serum stability;

[0053] (3) Enzyme stability: The samples prepared in Example 1 were incubated with different concentrations (0, 12.5, 25, 50, 100, 200 and 400 μg / mL) of RNase A at 37°C for 1 h, or incubated in 25 μg / mL RNase A for different time gradients (0, 1, 2, 4, 6, 12 and 24 h) to test the enzyme stability.

[0054] 2. Experimental results

[0055] Serum stability results Figure 1 As shown in Figure 1, as the concentration of co-incubated fetal bovine serum (FBS) gradually increased (1-10%), the nanobox structure gradually disintegrated, and more and more free siRNA came out. However, it can be observed that after 24 hours of incubation with 10% FBS, 60% of the undegraded free siRNA remained, and clear bands were identified. After incubation with 10% FBS for different time periods, some siRNA was still encapsulated in the nanobox at 12 hours, and it was not completely dissociated until 24 hours. Then, siR-TDN box After incubation with different concentrations of RNase A for 1 h, when the enzyme concentration was increased to 400 μg / mL, only 10.9% of the undegraded free siRNA remained, but the nanobox exoskeleton remained intact ( Figure 1 ). Next, we further studied the siR-TDN box In the degradation curve of 25 μg / mL RNase A over time, the siRNA band can still be seen at 12 hours ( Figure 1 ). This shows that siR-TDN box It can make siRNA have good storage stability and facilitate transportation, and can also protect siRNA from degradation by enzymes and serum under conditions simulating the in vivo environment.

[0056] Experimental Example 3: Cell Experiment

[0057] 1. Experimental methods

[0058] (1) Cell culture: In vitro study of siR-TDN using NIH / 3T3 mouse embryonic fibroblasts boxThe cells were cultured in DMEM medium containing 10% fetal bovine serum. Doxorubicin was used to induce cell senescence. The specific operation was as follows: 0.1 μM doxorubicin was used twice every 1 day, and the subsequent experiment was performed 7 days later. siRNA (i.e., double-stranded siRNA in Example 1) with a final concentration of 200 nM, NC-siRNA, TDN box 、siR-TDN box Or treat cells with rapamycin (Rapa) at a final concentration of 50 μg / L for 24 hours. The young cell group without adriamycin induction treatment is called the Control group.

[0059] (2) Cellular uptake: The Cy5 fluorescent group is connected to the sense strand of siRNA to obtain Cy5-siR-TDN box Flow cytometry and confocal laser scanning microscopy analysis of siR-TDN box Cytosolic profile of DOX in young (Control) and aged (DOX-sen) cells.

[0060] (3) In vivo imaging: Six-week-old male C57BL / 6 mice were used to study Cy5-siR-TDN box Distribution in the body. The mouse abdomen was depilated with depilatory cream one day before the experiment. 1 nM Cy5-siR-TDN was injected intraperitoneally 24 / 12 / 6 / 3 / 1 / 0.5 h before imaging. box 100 μL. After capturing whole-body fluorescence images under isoflurane gas anesthesia, the mice were euthanized and dissected for further organ fluorescence imaging.

[0061] (4) Senescence-associated β-galactosidase (SA-β-Gal): The senescence-associated β-Gal activity in the sample cells was determined according to the manufacturer's instructions (C0602; Beyotime, China). The wells were sealed with a sealing film to prevent the evaporation of the staining medium. After incubation overnight, the cells were washed with PBS and observed under a bright field microscope. Western Blot and immunofluorescence staining were used to analyze the expression of senescence-associated proteins p16 and p21; the expression of senescence-associated secretory phenotypes (IL-6, TNF-a); and the expression of the mTORC1 signaling pathway (S6, p-S6).

[0062] 2. Experimental results

[0063] Figure 2 siR-TDN boxDistribution in cells and tissues. The results showed that flow cytometry analysis showed that at 3h, young cells (Control) took up more siR-TDN than doxorubicin-induced senescent cells (DOX-sen). box However, there was no significant difference in the uptake of the two cells at 6h and 12h ( Figure 2 At 12 h, almost 90% of siR-TDN box The siR-TDN is taken up into the cells. Under a fluorescent microscope, it can be observed that young fibroblasts are spindle-shaped, while the aging cells become flat, larger in size, and have larger nuclei. box After 12 hours of treatment, almost 100% of the cells showed red fluorescence, which was evenly distributed in the cytoplasm ( Figure 2 ). box After 24 h of incubation, the fluorescence intensity of Cy5 in the young cell (Control) group and the senescent cell (DOX-sen) group remained at the same level, with no statistical difference ( Figure 2 ). This suggests that siR-TDN box It has an excellent ability to enter senescent cells.

[0064] As for the distribution of the drug in vivo, the results of bioluminescence imaging analysis showed that siR-TDN box 30 minutes after intraperitoneal injection, the Cy5 fluorescence signal of siRNA was first transported by the circulatory system to tissues with faster blood flow rates in the body, such as the heart, liver, and lungs. 1 hour after administration, the fluorescence signal began to appear in the kidneys, and the fluorescence peak did not appear in the kidneys until 3 hours, confirming that siR-TDN box The renal excretion of siRNA is relatively slow. After 24 hours of administration, the fluorescent signal is still retained in the liver and kidney of mice, which suggests that the encapsulation of the nanobox may help protect siRNA from escaping clearance ( Figure 2 ). Therefore, siR-TDN box It can be considered as a highly efficient siRNA delivery system that can quickly penetrate into senescent cells, which is the key to improving the bioavailability of therapeutic siRNA.

[0065] Figure 3 siR-TDN box It can alleviate doxorubicin-induced cell senescence. Figure 3 a is a schematic diagram of the anti-aging cell experimental treatment. Figure 3 b qPCR was used to detect the relationship between senescent cells and siRNA and TDN box 、siR-TDN box The expression of Raptor mRNA after 24h incubation. It can be seen that the expression of Raptor mRNA increased after siRNA treatment, and TDNbox 、siR-TDN box After treatment, the expression of Raptor mRNA decreased. box and siR-TDN box The difference in Raptor mRNA expression between the aging control group and the Dox group after treatment showed that siR-TDN box The expression of Raptor mRNA was reduced more significantly after siRNA treatment and TDN box The sum of the effects of reducing the expression of Raptor mRNA after treatment indicates that siR-TDN box It has a synergistic effect in reducing the expression of Raptor mRNA.

[0066] Table 1. Expression of Raptor mRNA after treatment in different experimental groups

[0067]

[0068] Figure 3 c shows representative images of senescent cells and control cells in the presence of SA-β-Gal dye and Figure 3 d shows the statistical analysis of the percentage of SA-β-Gal positive cells in mouse NIH / 3T3 cells after treatment (see Table 2). box 、siR-TDN box After treatment with siRNA and Rapa, the number of senescent cells decreased. box 、siR-TDN box The percentage of senescent cells after treatment with Rapa was reduced compared with the Dox-sen group, and siR-TDN box The effect of reducing senescent cells after treatment was greater than that after siRNA treatment and TDN box The sum of the effects of reducing senescent cells after treatment indicates that siR-TDN box It exerted a synergistic effect in reducing the number of doxorubicin-induced senescent cells.

[0069] Table 2. Number of senescent cells in the presence of SA-β-Gal dye

[0070]

[0071] Figure 3 e The changes in the protein levels of senescence markers (p21 and p16), mTORC1 pathway (Raptor, S6, and p-S6), and SASP factors (IL-6 and TNF-α) after doxorubicin-induced senescence were detected by immunoblotting and Figure 3(fg) shows the statistical analysis of the expression levels of p21 (see Table 3), p16, Raptor, p-S6 / S6, IL-6, and TNF-α. box 、siR-TDN box The expression of p21 was decreased after treatment of doxorubicin-induced senescent cells by siRNA, TDN, and Rapa. box 、siR-TDN box After treatment with Rapa, the percentage of p21 expression was reduced compared with that of Dox-sen group. box The expression of p21 was reduced more significantly after siRNA treatment and TDN box The sum of the effects of reducing p21 expression after treatment indicates that siR-TDN box It has a synergistic effect in reducing the expression of p21 in senescent cells.

[0072] Table 3. Expression of p21 after treatment in different experimental groups

[0073]

[0074] The above experimental results show that siR-TDN box It can effectively inhibit doxorubicin-induced cell senescence, and siR-TDN box The anti-aging effect is greater than siRNA and TDN box The sum of the anti-aging effects of the ingredients has a synergistic effect.

[0075] Experimental Example 4: In vivo animal experiment

[0076] 1. Experimental methods

[0077] To induce accelerated aging in C57BL / 6 male mice, doxorubicin was injected intraperitoneally (twice, 10 days apart, at a dose of 10 mg / kg). In the lifespan experiment, to detect the extension of mouse lifespan, mice received doxorubicin and siR-TDN box (200uL, every other day) until all mice died. In order to detect the physical function of mice in the healthy lifespan experiment, mice were intraperitoneally injected with doxorubicin (twice, 10 days apart, at a dose of 10 mg / kg) and drugs (the drugs in each group were siRNA (1μM, 200uL), TDN box (1μM, 200uL), siR-TDN box(1μM, 200uL) or rapamycin (4mg / Kg); every other day for 4 weeks. Naturally aged C57BL / 6 mice (also known as old mice, male, 17 months old) and young mice (4 weeks old when purchased) were used as controls. The control group and doxorubicin group mice were given 200uL of normal saline. At the end of the experiment, the mice were euthanized and samples were collected.

[0078] (2) Behavioral experiments

[0079] a) Grip strength: Mice were placed on top of a grid strength meter (YLS-13A) so they gripped the grid with all four paws. The mice were pulled by their tails until they were released and grip force was recorded over five trials. Grip force (g) was averaged, excluding maximum and minimum data points.

[0080] b) Pole climbing test: The apparatus used consisted of a 1 cm diameter, 50 cm long, 45° tilted wooden stick and a 2.5 cm diameter wooden ball on top of the stick. The researchers asked the mice to turn around and climb down the stick with their front paws on the ball, and then recorded the time they took to turn around and climb down the stick.

[0081] c) Rotarod test: To assess the motor coordination and balance of mice. The device was set to accelerate from 4 to 44 revolutions in 300 seconds. The time and distance the mouse fell from the rod were recorded. Each mouse was tested twice, with an interval of 1 hour between each test.

[0082] d) Open field test: To evaluate the exploratory behavior of mice in unfamiliar environments, the mice were placed in a 50 cm × 50 cm × 50 cm square open area, and the time and distance the mice explored the central area were recorded.

[0083] (3) Intraperitoneal glucose tolerance test

[0084] After the designated fasting period, mice were intraperitoneally injected with glucose (2 g / kg). Blood glucose was recorded with a glucometer at 0, 15, 30, 60, and 120 min.

[0085] (4) Biochemical index test

[0086] Serum was collected and tested for serum biochemical tests. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), urea, and creatinine (CRE) in aging mice tended to increase, but there was no significant difference. This indicates that the liver and kidney functions of aging mice tended to weaken, but there was no substantial damage.

[0087] 2. Experimental results

[0088] Figure 4 siR-TDN box Slowed down the aging process in doxorubicin-exposed mice. Figure 4a is a schematic diagram of the mouse experiment. Figure 4 b shows that in siR-TDN box After treatment, the survival curve of aging mice was improved and prolonged. Figure 4 (cg) shows siR-TDN box Behavioral experimental results of mice exposed to doxorubicin after treatment. Figure 4 c shows the quantitative results of the grip strength of mice after treatment in each group. It can be seen that compared with the Dox group, siRNA, TDN box 、siR-TDN box The grip strength of mice was enhanced after treatment with siRNA and Rapa. box 、siR-TDN box The percentage of grip strength improvement of mice in the Dox group after treatment with Rapa was found to be box The grip strength enhancement effect of mice treated with siRNA was greater than that of mice treated with TDN. box The sum of the grip strength enhancement effects after treatment indicates that siR-TDN box It exerted a synergistic effect in enhancing the grip strength of Dox-induced aged mice.

[0089] Table 4. Quantification of changes in grip strength test of mice after treatment in each group

[0090]

[0091] Figure 4 h The results of the inflammatory areas of mice in each group after treatment were obtained by H&E staining of liver sections; Figure 4 i shows the visualization (left) and quantitative (right) analysis results of the percentage of SA-β-gal positive senescent cells in the liver. Figure 4 j shows representative visualization of p21 immunofluorescence in the liver of doxorubicin-exposed mice after the indicated treatments (left) and quantitative results of the percentage of p21-positive senescent cells in the liver (right). box 、siR-TDN box The number of p21-positive senescent cells decreased after treatment with siRNA and Rapa. box 、siR-TDN box The percentage of p21-positive senescent cells decreased after treatment with Rapa compared with the Dox group. box The reduction of p21-positive senescent cells after treatment was greater than that after siRNA treatment and TDN box The sum of the reduction effects of p21-positive senescent cells after treatment indicates that siR-TDN boxIt exerted a synergistic effect in reducing the number of senescent cells in Dox-induced aging mice.

[0092] Table 5. Percentage of p21-positive senescent cells in the liver

[0093]

[0094] Figure 5 siR-TDN box It can improve the physical skills of old mice (referring to mice that have aged naturally). The results show that the hair on the back of old mice (center) is grayer, less shiny, and larger in volume than that of young mice (left). siR-TDN box The back hair of the mice in the treatment group (right) regained its dark and shiny color, but there was no significant difference in body weight compared with the saline treatment group ( Figure 5 b) The mice were then assessed for physical function using a battery of functional tests, all of which were reduced in aged mice. box Treatment significantly increased the grip strength of aged mice ( Figure 5 c) Maximum rotation time ( Figure 5 f), total movement distance ( Figure 5 g), and reduces turning time and climb-down time ( Figure 5 d, e). The results of the open field test showed that compared with young control mice, the old mice explored the central area less in terms of time and distance, while siR-TDN box The treated mice showed an increased tendency to explore the central region ( Figure 5 h,i). The results of functional analysis of these mice showed that motor function, balance ability, exercise endurance, and spontaneous exploration ability were improved. In order to determine the possible changes in liver and kidney function in aged mice, serum biochemical tests were performed. There was a trend of increase in aspartate aminotransferase (AST), alanine aminotransferase (ALT), urea (urea), and creatinine (CRE) in aged mice, but there was no significant difference ( Figure 5 j). This indicates that the liver and kidney functions of aged mice tend to weaken, but there is no substantial damage. siR-TDN box The treatment did not impair liver and kidney function. Considering that rapamycin treatment can cause glucose intolerance, the siR-TDN box Mice treated for 8 weeks underwent a glucose tolerance test and found that siR-TDN box No effect on glucose tolerance in aged mice ( Figure 5 k).

[0095] Figure 6 siR-TDN boxThe results showed that senescent cells accumulated in different tissues of aged mice, which was consistent with the observed increase in SA-β-gal positive cells in the liver, kidney and lung of aged mice. box Reduced SA-β-gal positive cells in liver, kidney and lung tissues of aged mice ( Figure 6 a). Aging is often accompanied by the accumulation of low-level chronic inflammation, which further accelerates aging, forming a vicious cycle. A large number of inflammatory cell infiltrations can be observed in the liver, kidney and lung sections of aged mice. box Suppressed inflammation in liver, kidney, and lung tissues of naturally aged mice ( Figure 6 b).

[0096] Immunofluorescence staining results showed that p21 expression was upregulated in the liver, kidney and lung of naturally aged mice. box After 8 weeks of treatment, mice showed effective senolytic activity ( Figure 6 c) Protein quantitative analysis showed that compared with the young control group and the saline treatment group, siR-TDN box Treatment reduced Raptor expression in aged mice, which in turn inhibited mTORC1 activity (measured by pS6 / S6). In addition, expression of aging markers, including the CDK inhibitors p16 and p21 ( Figure 6 d) Down-regulation. In summary, siR-TDN box Demonstrated highly efficient Raptor silencing without significant side effects.

[0097] The above experimental results show that siR-TDN box It can effectively inhibit doxorubicin-induced senescence and natural senescence in vivo, and siR-TDN box The anti-aging effect is greater than siRNA and TDN box The sum of the anti-aging effects of the ingredients has a synergistic effect.

[0098] In summary, the present invention provides a tetrahedral framework nucleic acid carrying siRNA, a preparation method thereof, and use thereof in the preparation of anti-aging drugs. The present invention carries siRNA that inhibits the expression of rapamycin complex 1 (mTORC1) onto a tetrahedral framework nucleic acid, and the formed tetrahedral framework nucleic acid complex can exert a synergistic anti-aging effect, and the tetrahedral framework nucleic acid complex has good application prospects in the preparation of anti-aging drugs.

Claims

1. A tetrahedral framework nucleic acid complex, characterized in that: The invention is a product prepared by using siRNA and tetrahedral framework nucleic acid as raw materials, wherein the molar ratio of siRNA to tetrahedral framework nucleic acid is 1:(0.5-10), and siRNA is siRNA for inhibiting the expression of rapamycin complex 1.

2. The tetrahedral framework nucleic acid complex according to claim 1, characterized in that The molar ratio of the siRNA to the tetrahedral framework nucleic acid is 1:

1.

3. The tetrahedral framework nucleic acid complex according to claim 1 or 2, characterized in that: The tetrahedral framework nucleic acid is self-assembled from four DNA single strands, and the sequences of the four DNA single strands are shown as SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3 and SEQ ID NO.4 respectively; The siRNA is self-assembled from two RNA single strands, and the sequences of the two RNA single strands are shown as SEQ ID NO.5 and SEQ ID NO.6 respectively.

4. A method for preparing the tetrahedral framework nucleic acid complex according to any one of claims 1 to 3, characterized in that: The method comprises the following steps: mixing siRNA and tetrahedral framework nucleic acid and reacting them to obtain a tetrahedral framework nucleic acid complex.

5. The method according to claim 4, characterized in that The reaction conditions are heating reaction first, then cooling reaction; The heating reaction temperature is 80-100°C and the time is 5-15min; The temperature of the cooling reaction is 0-10°C and the time is 10-30 minutes.

6. The method according to claim 5, characterized in that The heating reaction temperature is 95°C and the time is 10 minutes; The temperature of the cooling reaction is 4°C and the time is 20 minutes.

7. Use of the tetrahedral framework nucleic acid complex according to any one of claims 1 to 3 in the preparation of anti-aging drugs.

8. The use according to claim 7, characterized in that The drug is a drug that inhibits the expression of Raptor mRNA and / or inhibits the expression of aging markers.

9. The use according to claim 7, characterized in that: The drug is a drug that reduces the number of senescent cells.

10. The use according to any one of claims 7 to 9, characterized in that: The drug is a drug preparation prepared by taking the tetrahedral framework nucleic acid complex as the active ingredient and adding pharmaceutically acceptable auxiliary materials.

Citation Information

Patent Citations

  • Tetrahedral framework nucleic acid targeting RAGE and application of tetrahedral framework nucleic acid

    CN117106775A

  • Dendrimer conjugates of small molecule biologics for intracellular delivery

    CN118043076A

  • Bone regenerating implants

    KR1020200078287A